Prostaglandin E2 for Cervical Ripening: A Multicenter Study of Patients with Prior Cesarean Delivery

Bruce L. Flamm; Deborah Anton; Janice R. Goings; Jeannie Newman

doi:10.1055/s-2007-994118

American Journal of Perinatology, Table of Contents

Am J Perinatol 1997; 14(3): 157-160
DOI: 10.1055/s-2007-994118

ORIGINAL ARTICLE

Prostaglandin E₂ for Cervical Ripening: A Multicenter Study of Patients with Prior Cesarean Delivery

Bruce L. Flamm, Deborah Anton, Janice R. Goings, Jeannie Newman

Departments of Obstetrics and Gynecology, Kaiser Permanente Medical Centers, Los Angeles, Riverside, and San Diego Counties, California

Abstract

ABSTRACT

To evaluate the maternal and fetal outcomes of a large cohort of women treated with prostaglandin E² (PGE²) gel for cervical ripening prior to trial of labor after previous cesarean delivery. Beginning in 1990 all pregnant patients with previous cesarean delivery presenting for prenatal care at 10 California hospitals were prospectively studied. We analyzed multiple parameters to compare outcomes of cases in which PGE² gel was used to outcomes in a control group in which PGE² was not used. Data were examined by X₂ testing. During the study period 5022 patients underwent trial of labor after prior cesarean delivery. Of these 5022 patients, 453 (9%) were treated with PGE₂ gel. There was no significant difference in the incidence of uterine rupture between the PGE₂ group and the control group. Indicators of maternal and perinatal morbidity were not significantly higher in the prostaglandin treated group. The use of PGE₂ gel for cervical ripening appears to be relatively safe in patients with prior cesarean delivery.

Keywords

Previous cesarean section - trial of labor - prostaglandin

Full Text